Autolus Therapeutics (AUTL) EBT (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of EBT data on file, last reported at -$91.5 million in Q4 2025.

• For the quarter ending Q4 2025, EBT fell 250.04% year-over-year to -$91.5 million; the trailing twelve-month figure through Dec 2025 stood at -$285.6 million (down 30.31% YoY), and the FY2025 full-year result was -$285.6 million, down 30.31% from the prior year.
• EBT for Q4 2025 stood at -$91.5 million, down from -$78.6 million in the prior quarter.
• Across five years, EBT topped out at -$7.4 million in Q4 2022 and bottomed at -$39.4 billion in Q3 2021.
• The 5-year median for EBT is -$45.7 million (2023), against an average of -$2.0 billion.
• The widest annual swing landed in 2021, when EBT plunged 87053.61%; it then surged 99.89% in 2022.
• A 5-year view of EBT shows it stood at -$24.1 million in 2021, then soared by 69.23% to -$7.4 million in 2022, then tumbled by 939.1% to -$77.2 million in 2023, then surged by 66.13% to -$26.1 million in 2024, then plunged by 250.04% to -$91.5 million in 2025.
• The last three EBT figures came in at -$91.5 million (Q4 2025), -$78.6 million (Q3 2025), and -$47.5 million (Q2 2025), per Business Quant data.

Peer Comparison